Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 77.1% | 5,778.2% | 238.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 71.7% | 59.8% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -207.8% | -618.5% | -48,373.7% | -249,111.2% |
| Other Income/Exp. Net | -$0 | $0 | $1 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | -400.9% | -575.7% | -6,556.7% | -195,450.4% |
| EPS | -0.002 | -0.002 | -0 | -0.003 |
| % Growth | -26.7% | -400% | 89.3% | – |
| EPS Diluted | -0.002 | -0.002 | -0 | -0.003 |
| Weighted Avg Shares Out | 478 | 478 | 478 | 449 |
| Weighted Avg Shares Out Dil | 478 | 478 | 478 | 449 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$0 | -$2 |
| % Margin | -187.3% | -601.9% | -5,586.6% | -245,958.6% |